Quenched Fluorescent Peptide Substrates as Tools for the Discovery of Novel Cardiovascular Disease Biomarkers
The generation of angiotensin II (Ang II) within the renin-angiotensin system (RAS) is recognised as a critical point in the regulation of cardiovascular function The final step in the production of Ang II is catalysed by the membrane-bound ectoenzyme angiotensin converting enzyme (ACE), and inhibitors of ACE are the most widely prescribed therapy in the treatment of hypertension, heart failure, and myocardial infarction Six years ago, the homologous enzyme ACE2 was discovered (1, 2) Evidence thus far suggests that ACE2 may work in a counter-regulatory role to ACE, via the inactivation of Ang II, and the formation of the putative vasodilator, Ang 1–7 (see 3 for review) This hypothesis is supported by an increasing number of published reports, including the development of an ACE2 knock-out mouse displaying severe defects in cardiac contractility which were prevented by concomitant ablation of ACE (4) Within the cardiovascular system, ACE2 expression is normally relatively...
KeywordsAngiotensin Convert Enzyme ACE2 Activity ACE2 Activity Inhibitor ACE2 Level Western Immunoblot Analysis
The work was funded by an NH&MRC project grant awarded to A. I. Smith.
- 2.Donoghueet et al. Circ. Res. 2000;87:E1–E9.Google Scholar